Zimmer Biomet Holdings, Inc. (ZBH) Price Target Cut to $135.00
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) had its price target decreased by stock analysts at BMO Capital Markets from $140.00 to $135.00 in a research report issued on Thursday. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 11.00% from the stock’s current price.
ZBH has been the topic of a number of other research reports. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 8th. Morgan Stanley upped their target price on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a report on Monday, July 17th. Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Monday, August 14th. Canaccord Genuity downgraded Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and reduced their target price for the stock from $141.00 to $135.00 in a report on Friday, July 28th. Finally, Needham & Company LLC reiterated a “strong-buy” rating and set a $153.00 target price on shares of Zimmer Biomet Holdings in a report on Wednesday, July 12th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Zimmer Biomet Holdings has an average rating of “Hold” and an average target price of $135.60.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. During the same quarter last year, the company posted $1.79 EPS. The firm’s revenue was down .8% on a year-over-year basis.
A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Zimmer Biomet Holdings by 4.1% in the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after acquiring an additional 679,080 shares in the last quarter. Vanguard Group Inc. lifted its position in Zimmer Biomet Holdings by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock valued at $1,718,057,000 after acquiring an additional 339,106 shares in the last quarter. State Street Corp lifted its position in Zimmer Biomet Holdings by 2.4% in the 1st quarter. State Street Corp now owns 8,193,165 shares of the medical equipment provider’s stock valued at $1,000,463,000 after acquiring an additional 191,747 shares in the last quarter. Longview Partners Guernsey LTD lifted its position in Zimmer Biomet Holdings by 17.7% in the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after acquiring an additional 1,128,973 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Zimmer Biomet Holdings by 8.1% in the 3rd quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock valued at $487,721,000 after acquiring an additional 311,654 shares in the last quarter. 85.26% of the stock is currently owned by institutional investors and hedge funds.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.